Implantica AG secured FDA approval for its product RefluxStop, announced its successful listing on the Nasdaq First North Premier Growth Market, and is headquartered in Vaduz, Liechtenstein.
2 reports, 2 independent
Updated Sep 11
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Implantica AG secured FDA approval for its product RefluxStop, announced its successful listing on the Nasdaq First North Premier Growth Market, and is headquartered in Vaduz, Liechtenstein.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Stockholm
capital and largest city of Sweden
-
Liechtenstein
country in Central Europe
- FDA
Related events
- Cronus Pharma LLC, headquartered in East Brunswick, is launching products in the U.S. market and seeking FDA approval.
- Cardiol Therapeutics Inc. is listed on Nasdaq and is developing therapy for an FDA-approved indication.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Capricor Therapeutics is seeking regulatory approval from the FDA for clinical trials and has listed on the Nasdaq stock exchange, with a law firm based in New York City involved.
- Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.